Dr Jose Puig Rivera, MD | |
410 Calle Mendez Vigo, Oficina 202, Dorado, PR 00646-4800 | |
(787) 278-2828 | |
Not Available |
Full Name | Dr Jose Puig Rivera |
---|---|
Gender | Male |
Speciality | Physical Medicine And Rehabilitation |
Experience | 27 Years |
Location | 410 Calle Mendez Vigo, Dorado, Puerto Rico |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1861432148 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208100000X | Physical Medicine & Rehabilitation | 15172 (Puerto Rico) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Doctors' Center Hospital, Inc | Manati, PR | Hospital |
Mailing Address | Practice Location Address |
---|---|
Dr Jose Puig Rivera, MD 410 Calle Mendez Vigo, Oficina 202, Dorado, PR 00646-4800 Ph: (787) 278-2828 | Dr Jose Puig Rivera, MD 410 Calle Mendez Vigo, Oficina 202, Dorado, PR 00646-4800 Ph: (787) 278-2828 |
News Archive
Many people have speculated on the evolutionary functions of the human orgasm, but the underlying mechanisms have remained mysterious. In a new paper, a Northwestern University researcher seeks to shed light on how orgasm works in the brain.
In a small, phase I clinical trial, Johns Hopkins Kimmel Cancer Center researchers say they show for the first time that the experimental drug guadecitabine (SGI-110) is safe in combination with the chemotherapy drug irinotecan and may overcome resistance to irinotecan in patients with metastatic colorectal cancer.
A new program project grant from the National Cancer Institute will fund research by the Translational Center of Excellence for Lung Cancer Immunology at the Abramson Cancer Center of the University of Pennsylvania to improve the effectiveness of chimeric antigen receptor T cell therapy at fighting solid tumors.
NovaBay Pharmaceuticals, Inc., a clinical stage biotechnology company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic-resistant infections, today reported financial results for the first quarter of 2010.
Merck, known as MSD outside the United States and Canada, today announced results of new exploratory pre-specified analyses from the ongoing STARTMRK Phase III study of its integrase inhibitor ISENTRESS (raltegravir) Tablets in combination therapy compared to efavirenz in combination therapy in previously untreated adult HIV-1-infected patients.
› Verified 9 days ago
Mrs. Zaira I Rodriguez Almodovar, Physical Medicine & Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 408 Camino De Los Jobanes, Sabanera Dorado, Dorado, PR 00646 Phone: 787-547-4606 |